Login to Your Account

Probiodrug stock oscillates on Alzheimer's data as investors bank gains

By Cormac Sheridan
Staff Writer

Monday, June 12, 2017

DUBLIN – Shares in Probiodrug AG climbed by almost 19 percent during early trading Monday on topline data from an exploratory phase IIa trial of its first-in-class glutaminylcyclase (QC) inhibitor PQ912 in early stage Alzheimer's disease patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription